177 related articles for article (PubMed ID: 12516054)
1. French gene therapy group reports on the adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Position statement from the European Society of Gene Therapy.
European Society of Gene Therapy
J Gene Med; 2003 Jan; 5(1):82-4. PubMed ID: 12516054
[No Abstract] [Full Text] [Related]
2. Occurrence of leukaemia following gene therapy of X-linked SCID.
Kohn DB; Sadelain M; Glorioso JC
Nat Rev Cancer; 2003 Jul; 3(7):477-88. PubMed ID: 12835668
[TBL] [Abstract][Full Text] [Related]
3. Report of a second serious adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Position of the European Society of Gene Therapy (ESGT).
Gansbacher B;
J Gene Med; 2003 Mar; 5(3):261-2. PubMed ID: 12666192
[No Abstract] [Full Text] [Related]
4. Gene therapy. Second child in French trial is found to have leukemia.
Marshall E
Science; 2003 Jan; 299(5605):320. PubMed ID: 12531981
[No Abstract] [Full Text] [Related]
5. Gene therapy. As Gelsinger case ends, gene therapy suffers another blow.
Couzin J; Kaiser J
Science; 2005 Feb; 307(5712):1028. PubMed ID: 15718439
[No Abstract] [Full Text] [Related]
6. Gene therapy. Panel urges limits on X-SCID trials.
Kaiser J
Science; 2005 Mar; 307(5715):1544-5. PubMed ID: 15761128
[No Abstract] [Full Text] [Related]
7. Gene therapy. Seeking the cause of induced leukemias in X-SCID trial.
Kaiser J
Science; 2003 Jan; 299(5606):495. PubMed ID: 12543948
[No Abstract] [Full Text] [Related]
8. Safeguards for gene therapy trials.
FDA Consum; 2003; 37(3):5. PubMed ID: 12793378
[No Abstract] [Full Text] [Related]
9. Safety panel backs principle of gene-therapy trials.
Check E
Nature; 2002 Dec; 420(6916):595. PubMed ID: 12478252
[No Abstract] [Full Text] [Related]
10. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency.
McCormack MP; Rabbitts TH
N Engl J Med; 2004 Feb; 350(9):913-22. PubMed ID: 14985489
[No Abstract] [Full Text] [Related]
11. Gene therapy. RAC hears a plea for resuming trials, despite cancer risk.
Kaiser J
Science; 2003 Feb; 299(5609):991. PubMed ID: 12586909
[No Abstract] [Full Text] [Related]
12. LMO2 and gene therapy for severe combined immunodeficiency.
Fischer A; Abina SH; Thrasher A; von Kalle C; Cavazzana-Calvo M
N Engl J Med; 2004 Jun; 350(24):2526-7; author reply 2526-7. PubMed ID: 15190153
[No Abstract] [Full Text] [Related]
13. Gene therapy: therapeutic gene causing lymphoma.
Woods NB; Bottero V; Schmidt M; von Kalle C; Verma IM
Nature; 2006 Apr; 440(7088):1123. PubMed ID: 16641981
[TBL] [Abstract][Full Text] [Related]
14. Gene therapy for severe combined immune deficiency.
Qasim W; Gaspar HB; Thrasher AJ
Expert Rev Mol Med; 2004 Jul; 6(13):1-15. PubMed ID: 15236670
[TBL] [Abstract][Full Text] [Related]
15. The future of gene therapy.
Cavazzana-Calvo M; Thrasher A; Mavilio F
Nature; 2004 Feb; 427(6977):779-81. PubMed ID: 14985734
[No Abstract] [Full Text] [Related]
16. Gene therapy put on hold as third child develops cancer.
Check E
Nature; 2005 Feb; 433(7026):561. PubMed ID: 15703711
[No Abstract] [Full Text] [Related]
17. US authorities uphold suspension of SCID gene therapy.
Fox JL
Nat Biotechnol; 2003 Mar; 21(3):217. PubMed ID: 12610555
[No Abstract] [Full Text] [Related]
18. Gene therapy: X-SCID transgene leukaemogenicity.
Thrasher AJ; Gaspar HB; Baum C; Modlich U; Schambach A; Candotti F; Otsu M; Sorrentino B; Scobie L; Cameron E; Blyth K; Neil J; Abina SH; Cavazzana-Calvo M; Fischer A
Nature; 2006 Sep; 443(7109):E5-6; discussion E6-7. PubMed ID: 16988659
[TBL] [Abstract][Full Text] [Related]
19. Cancer risk prompts US to curb gene therapy.
Check E
Nature; 2003 Mar; 422(6927):7. PubMed ID: 12621402
[No Abstract] [Full Text] [Related]
20. Gene therapists hopeful as trials resume with childhood disease.
Check E
Nature; 2004 Jun; 429(6992):587. PubMed ID: 15190314
[No Abstract] [Full Text] [Related]
[Next] [New Search]
